Asensus Surgical, Inc. Announces Hirosaki University Hospital to Launch Senhance Robotic Surgery Program
RESEARCH TRIANGLE PARK, NC – (BUSINESS WIRE) – Asensus Surgical, Inc. (NYSE American: ASXC), a medical technology company that is digitizing the surgeon-patient interface to usher in a new era in Performance-Guided Surgery ™, today announced it has joined Hirosaki University Hospital a Agreement to lease and use a Senhance® Surgical System.
“We are excited to add a system to Hirosaki University Hospital to help expand its Senhance Robotic Surgery program,” said Anthony Fernando, President and CEO of Asensus Surgical. “We are very encouraged by the ongoing momentum in Japan and look forward to further expanding our presence in the region.”
Asensus Surgical’s technology platform, Senhance Surgical System, is the first of its kind digital laparoscopic platform that uses advanced intelligence to deliver unmatched performance and patient outcomes through machine learning. Senhance goes beyond the typical surgical robotic systems and offers surgical safety through haptic feedback, eye tracking camera control and 3D visualization and is the first platform to offer 3 mm instruments (the smallest instrument available worldwide on a robotic surgical platform) . . Senhance’s surgical system is powered by the Intelligent Surgical Unit ™ (ISU ™). The ISU enables a surgeon to machine vision control of the camera by responding to commands and recognizing specific objects and locations in the surgical field, and enables a surgeon to change the visualized field of view by moving their instruments. The latest ISU features extend these capabilities and introduce advanced features including: 3D measurement, digital tagging, image enhancement and improved camera control based on real-time data from anatomical structures during surgery.
“The initiation of the Senhance program adds to our emphasis on delivering innovative medicine,” said Dr. Kenichi Hakamada, professor and chairman of the Department of Gastroenterological Surgery Department of Pediatric Surgery. “We look forward to exploring the potential of Senhance as a novel and differentiated treatment option for our patients and as a powerful tool for our physicians.”
About Hirosaki University Hospital
Since 1944, Hirosaki University Hospital has grown into one of the most respected centers for medical care, clinical research, and medical education in northern Japan. Hirosaki University Hospital’s mission is to practice cutting-edge medicine, provide advanced medical education, and conduct innovative medical research in accordance with established ethical standards, thereby bringing and contributing to the lives of patients, both physical and mental health and hope to do for the good of the community.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the surgeon-patient interface to usher in a new era in performance-guided surgery by unlocking surgeons clinical intelligence to enable consistently superior outcomes and a new standard of surgery. This builds on the foundation of digital laparoscopy with the Senhance Surgical System powered by the Intelligent Surgical Unit (ISU) to improve surgeon control and reduce surgical variability. With the introduction of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive, and economic deficiencies that drive surgical outcomes and value-based healthcare. Find out more about performance-guided surgery and digital laparoscopy with the Senhance Surgical System here: www.senhance.com. Now available for sale in the US, EU, Japan, Russia, and select other countries. A full list of application areas can be found at: www.senhance.com/indications. More information is available at www.asensus.com.
This press release contains statements about the Senhance Surgical System and Hirosaki University Hospital starting a program with the Senhance System. These statements and other statements regarding our future plans and goals constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to promote the safe haven of. qualify liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, beyond our control, and which could cause results to differ materially from expectations from Hirosaki University Hospital along with our dedicated training center in Japan and a growing number of active systems at reputable sites Institutions will continue to accelerate the rollout of the Senhance system in the Asia-Pacific region in the future. For a discussion of the risks and uncertainties relating to the company’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC was filed on March 11, 2021 and our other filings that we are making with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We assume no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or for any other reason.